Human Life Code Co., Ltd.
Comparison of characteristics based on comprehensive gene expression analysis of mesenchymal cells derived from the umbilical cord and those derived from other tissues was presented at the 23rd Japanese Society for Regenerative Medicine.
……
Human Life Code Co., Ltd. (President: Masamitsu Harada, location: Chuo-ku, Tokyo, hereinafter referred to as the “Company”) aims to be the first in the world to commercialize umbilical cord-derived mesenchymal cells as regenerative medical products. At the 23rd General Meeting of the Japanese Society for Regenerative Medicine, which was held from March 21st (Thursday) to March 23rd (Saturday) at the Niigata Convention Center Toki Messe, a presentation titled “Umbilical Cord-Derived Mesenchymal Cells and Other Tissue-Derived Mesenchymal Cells” was held at the Niigata Convention Center Toki Messe. A poster presentation was given on “Characteristic Comparison by Comprehensive Gene Expression Analysis of Cells” and a lively exchange of opinions was held with the participating researchers.
[Image 1: https://prtimes.jp/i/61963/21/resize/d61963-21-547896f2463c1ea027a2-0.png&s3=61963-21-66979146572850c5e4c4d7fc92e759bb-602×276.png ]
■Presentation topic/presenter
Title: Comparison of characteristics of umbilical cord-derived mesenchymal cells and mesenchymal cells derived from other tissues through comprehensive gene statement analysis
Presenters: Kazuhiro Hitomi1), Akiko Mitani1), Tokiko Nagamura2), Mayo Yamada1) 1) Human Life Code Co., Ltd.
2) Department of Cell Processing and Blood Transfusion, Institute of Medical Science, The University of Tokyo
■Background
[Image 2: https://prtimes.jp/i/61963/21/resize/d61963-21-524c450aab8335319371-1.jpg&s3=61963-21-a9cc3b8ef0c1b2f3246bdede7703f526-2025×2700.jpg] Mesenchymal Stromal Cells (MSCs) are cells with differentiation potential that can be collected from a wide variety of tissues such as umbilical cord, bone marrow, fat, and dental pulp. MSCs are known to have immunomodulatory effects and tissue repair abilities, and in recent years, research and development of therapeutic methods using MSCs has been attracting attention as a new drug discovery modality. Among them, umbilical cord-derived mesenchymal stromal cells (UC-MSCs) are said to have several advantages over MSCs derived from other tissues, such as cell uniformity and high cell proliferation ability. Although there have been reports, there have been limited reports on the differences at the gene expression level that explain them. In this study, we clarified the characteristics of UC-MSCs based on the results of comprehensive gene expression analysis using RNA-seq analysis.
■Results
RNA of MSCs derived from human umbilical cord, bone marrow, and adipose tissue was purified and subjected to RNA-seq analysis, and based on the data obtained, principal component analysis and cluster analysis were performed. It has become clear that the gene expression patterns of tissue-derived MSCs are different.
In particular, as a result of investigating factors whose expression changes in UC-MSCs, it was revealed that there are differences in the expression of secreted factors, cell membrane constituent factors, transcription factors, etc. that may be linked to the functions of MSCs.
■Outlook
By utilizing the data obtained this time, we will lead to further elucidation of the functions of MSCs, such as immunomodulatory effects and tissue repair abilities, which have not yet been fully elucidated. ■Comment from Mayo Yamada, our executive officer and CSO
At this year’s Japan Society for Regenerative Medicine, the potential for treating intractable diseases using mesenchymal cells or their exosomes, including our company, was greatly demonstrated. We are deepening our confidence in the usefulness of UC-MSCs in the development of regenerative medicine products, which has been supported by our company’s announcement, and in the expectations of everyone. With the spirit of continuing to lead treatments
internationally, we will continue to develop products that will reach patients as soon as possible.
[About Human Life Code] (https://humanlifecord.com/)
Human Life Cord Co., Ltd. manufactures and develops cell products from umbilical cords (“cords”) that are domestically produced and stockpilable, and provides hope for life to patients with intractable diseases for which there is currently no established treatment (“cords”). ), which will lead to future medical care aimed at preventing the aggravation of diseases that will extend healthy life expectancy (the “code”), thereby creating a society in which everyone can live a fulfilling life (the “human life”). ) is our vision. In 2019, won the Grand Prize and Tokyo Governor’s Award at the 1st Tokyo Venture Company Championship. Selected as a company eligible for support from the “Deep Ecosystem” operated by the “Startup Ecosystem Tokyo Consortium” sponsored by the Tokyo Metropolitan Government. Received the Minister of Health, Labor and Welfare Award at the 5th Japan Open Innovation Awards sponsored by the Cabinet Office in 2023. A company selected for the startup support program “J-Startup” by the Ministry of Economy, Trade and Industry in 2023.
More details about this release:
https://prtimes.jp/main/html/rd/p/000000021.000061963.html